Legochem Biosciences, Inc.

Kyu Man Oh

Yong Zu Kim

Sung Ho Woo

Hyang Sook Lee

Chul-Woong Chung

Tae Kyo Park

Sun Young Kim

Ho Young Song

Jeiwook Chae

Yeong Soo Oh

Young Lag Cho

Yun Hee Park

Jeong Hee Ryu

Ji Young Min

Hyun Jin Kwon

Jong Un Cho

Dae Hyuck Kang

Doo Hwan Jung

Jeon Yang

Min Soo Kim

Chul Soon Park

Sung Min Kim

Sang Eun Chae

Sung Yoon Baek

Hye Kyung Chang

Joung Yul Yun

Soo Bong Ha

Young Jae Yang

Jeung Hie Choi

Hye Jin Heo

Hye Jin Kang

Young Zu Kim

Jeung Soon Choi

Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Compounds comprising self-immolative group

Provided are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Substituted dihydroisoxazole derivatives useful as inhibitors of &#x3b2;-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.

Compositions and methods for inhibiting &#x3b2;-lactamase

Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.

Compositions and methods for inhibiting beta-lactamase

The present invention relates to novel cephalosporin derivatives represented by X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Cephalosporin derivatives and pharmaceutical compositions thereof

The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R, and Rare as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. Compounds of the present invention are effective ingredients for the broad spectrum of antibiotic resistance, exhibit low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.

Growing community of inventors

Daejeon, South Korea

Kyu Man Oh